Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Paragon Bioservices Acquires Systems for Use in Vaccine and Protein Manufacturing

Published: Wednesday, January 30, 2013
Last Updated: Wednesday, January 30, 2013
Bookmark and Share
Company accelerates the development and manufacturing of cell-based VLP-type vaccines using the MaxCyte Flow Electroporation Technology Platform.

MaxCyte, Inc., the pioneer in scalable, high performance transient transfection systems, is pleased to announce that Paragon Bioservices has acquired both the MaxCyte VLX® Large Scale Transfection System and the MaxCyte STX® Scalable Transfection System for use in contract manufacturing of recombinant proteins, antibodies, viral vectors, vaccines, and VLPs. The initial application of MaxCyte STX and VLX systems will be in fulfillment of a Department of Defense contract for the process development and manufacturing scale-up of VLP-type vaccines against Ebola Zaire, Ebola Sudan, and Marburg viruses in support of the ongoing preclinical evaluation of the efficacy, potency, and safety of these Filovirus vaccine candidates.

“MaxCyte flow electroporation is the ideal transfection technology to meet Paragon’s needs for rapid protein development and production from mammalian and insect cells. The performance and scalability from the MaxCyte STX in the development stage to the MaxCyte VLX at full-scale manufacturing streamlines and accelerates the services we can offer to our clients,” says Marco Chacon, PhD, President and CEO of Paragon. “We believe that this platform will play a key role where performance and rapid response are necessary to meet the scientific and business objectives of our clients, while protecting human and animal health.”

“The ability to transiently transfect 2E11 mammalian cells with RNA or DNA using a single 30 minute run is unique in the industry and aligns perfectly with Paragon’s expertise in protein, virus, and vaccine production. We are delighted that Paragon values the speed, robustness, and scalability of MaxCyte transfection systems,” says Douglas Doerfler, President and CEO of MaxCyte. “With the addition of the MaxCyte STX and MaxCyte VLX, Paragon will be well positioned to provide a streamlined process to meet the development and manufacturing needs of all its global service clients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Unique Visual Stimulation May Be New Treatment for Alzheimer’s
Noninvasive technique reduces beta amyloid plaques in mouse models of Alzheimer’s disease.
Major Neuroscience Initiative Launched
Tianqiao and Chrissy Chen Institute invest $115 million to further expand neuroscience research, while Caltech construct $200 million biosciences complex.
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Genetics Control Regenerative Properties Of Stem Cells
Researchers define how genetic factors control regenerative properties of blood-forming stem cells.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!